Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 70

1.

Cancer therapy based on oncogene addiction.

McCormick F.

J Surg Oncol. 2011 May 1;103(6):464-7. doi: 10.1002/jso.21749. Review.

PMID:
21480237
2.

Drug discovery: inhibitors that activate.

Cichowski K, Jänne PA.

Nature. 2010 Mar 18;464(7287):358-9. doi: 10.1038/464358a. No abstract available.

PMID:
20237552
3.

Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer.

Roberts PJ, Der CJ.

Oncogene. 2007 May 14;26(22):3291-310. Review.

PMID:
17496923
4.

Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy.

Friday BB, Adjei AA.

Clin Cancer Res. 2008 Jan 15;14(2):342-6. doi: 10.1158/1078-0432.CCR-07-4790.

5.

The evolution of melanoma resistance reveals therapeutic opportunities.

Das Thakur M, Stuart DD.

Cancer Res. 2013 Oct 15;73(20):6106-10. doi: 10.1158/0008-5472.CAN-13-1633. Epub 2013 Oct 4. Review.

6.

Novel targets in solid tumors: MEK inhibitors.

Messersmith WA, Hidalgo M, Carducci M, Eckhardt SG.

Clin Adv Hematol Oncol. 2006 Nov;4(11):831-6. Review.

PMID:
17143253
7.

Novel mitogen-activated protein kinase kinase inhibitors.

Chapman MS, Miner JN.

Expert Opin Investig Drugs. 2011 Feb;20(2):209-20. doi: 10.1517/13543784.2011.548803. Review.

PMID:
21235429
8.

MEK inhibitors: a therapeutic approach to targeting the Ras-MAP kinase pathway in tumors.

Sebolt-Leopold JS.

Curr Pharm Des. 2004;10(16):1907-14. Review.

PMID:
15180527
9.

Targeting the RAF-MEK-ERK pathway in cancer therapy.

Montagut C, Settleman J.

Cancer Lett. 2009 Oct 8;283(2):125-34. doi: 10.1016/j.canlet.2009.01.022. Epub 2009 Feb 12. Review.

PMID:
19217204
10.

Advances in the development of cancer therapeutics directed against the RAS-mitogen-activated protein kinase pathway.

Sebolt-Leopold JS.

Clin Cancer Res. 2008 Jun 15;14(12):3651-6. doi: 10.1158/1078-0432.CCR-08-0333.

11.

The importance of Raf dimerization in cell signaling.

Freeman AK, Ritt DA, Morrison DK.

Small GTPases. 2013 Jul-Sep;4(3):180-5. doi: 10.4161/sgtp.26117. Epub 2013 Aug 28.

12.

Targeting the Raf kinase cascade in cancer therapy--novel molecular targets and therapeutic strategies.

Lee JT Jr, McCubrey JA.

Expert Opin Ther Targets. 2002 Dec;6(6):659-78. Review.

PMID:
12472379
14.

Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.

McCubrey JA, Steelman LS, Abrams SL, Lee JT, Chang F, Bertrand FE, Navolanic PM, Terrian DM, Franklin RA, D'Assoro AB, Salisbury JL, Mazzarino MC, Stivala F, Libra M.

Adv Enzyme Regul. 2006;46:249-79. Epub 2006 Jul 18.

PMID:
16854453
15.

Resistance to mitogen-activated protein kinase kinase (MEK) inhibitors correlates with up-regulation of the MEK/extracellular signal-regulated kinase pathway in hepatocellular carcinoma cells.

Yip-Schneider MT, Klein PJ, Wentz SC, Zeni A, Menze A, Schmidt CM.

J Pharmacol Exp Ther. 2009 Jun;329(3):1063-70. doi: 10.1124/jpet.108.147306. Epub 2009 Mar 3.

16.

The RAS/Raf1/MEK/ERK signaling pathway facilitates VSV-mediated oncolysis: implication for the defective interferon response in cancer cells.

Noser JA, Mael AA, Sakuma R, Ohmine S, Marcato P, Lee PW, Ikeda Y.

Mol Ther. 2007 Aug;15(8):1531-6. Epub 2007 May 15.

PMID:
17505473
17.

Lipocalin 2 diminishes invasiveness and metastasis of Ras-transformed cells.

Hanai J, Mammoto T, Seth P, Mori K, Karumanchi SA, Barasch J, Sukhatme VP.

J Biol Chem. 2005 Apr 8;280(14):13641-7. Epub 2005 Feb 3.

18.

Targeted therapy for thyroid cancer: striking the survival signaling.

Vitale M.

J Clin Endocrinol Metab. 2011 Apr;96(4):936-8. doi: 10.1210/jc.2011-0347. No abstract available.

PMID:
21474689
19.

Role of RAF/MEK/ERK pathway, p-STAT-3 and Mcl-1 in sorafenib activity in human pancreatic cancer cell lines.

Ulivi P, Arienti C, Amadori D, Fabbri F, Carloni S, Tesei A, Vannini I, Silvestrini R, Zoli W.

J Cell Physiol. 2009 Jul;220(1):214-21. doi: 10.1002/jcp.21753.

PMID:
19288493
20.

Targeting receptor kinases by a novel indolinone derivative in multiple myeloma: abrogation of stroma-derived interleukin-6 secretion and induction of apoptosis in cytogenetically defined subgroups.

Bisping G, Kropff M, Wenning D, Dreyer B, Bessonov S, Hilberg F, Roth GJ, Munzert G, Stefanic M, Stelljes M, Scheffold C, Müller-Tidow C, Liebisch P, Lang N, Tchinda J, Serve HL, Mesters RM, Berdel WE, Kienast J.

Blood. 2006 Mar 1;107(5):2079-89. Epub 2005 Nov 8.

Items per page

Supplemental Content

Write to the Help Desk